BioInvent International AB logo

BINV BTA - BioInvent International AB News Story

SEK1.7 0.0  0.0%

Last Trade - 12/08/20

Sector
Healthcare
Size
Small Cap
Market Cap £170.0m
Enterprise Value £108.5m
Revenue £12.6m
Position in Universe th / 1829

BRIEF-CASI Pharmaceuticals Partner, Bioinvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin's Lymphoma Patients

Thu 28th January, 2021 12:23pm
Jan 28 (Reuters) - BioInvent International AB  BINV.ST :
    * CASI PHARMACEUTICALS PARTNER, BIOINVENT, PRESENTS PHASE
I/IIA
DATA THAT SUGGESTS BI-1206 RESTORES ACTIVITY OF RITUXIMAB IN
RELAPSED NON-HODGKIN'S LYMPHOMA PATIENTS

Source text for Eikon:  ID:nPn7l5zMma 
Further company coverage:  BINV.ST 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.